Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Susan C Bolge, Natalia M Flores, Shu Huang & Jennifer Cai. (2017) Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes. International Journal of General Medicine 10, pages 177-187.
Read now
Read now
Nicole M Gerlanc, Jennifer Cai, Joseph Tkacz, Susan C Bolge & Brenna L Brady. (2017) The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin. Diabetes, Metabolic Syndrome and Obesity 10, pages 89-99.
Read now
Read now
Guntram Schernthaner, Fernando J. Lavalle-González, Jaime A. Davidson, Holly Jodon, Ujjwala Vijapurkar, Rong Qiu & William Canovatchel. (2016) Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Postgraduate Medicine 128:8, pages 725-730.
Read now
Read now
Lawrence Blonde, Kaj Stenlöf, Albert Fung, John Xie, William Canovatchel & Gary Meininger. (2016) Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine 128:4, pages 371-380.
Read now
Read now
Qiang Du, Yan-Jun Wang, Sheng Yang & Ping Han. (2015) Clinical utility and patient considerations in the use of the sitagliptin–metformin combination in Chinese patients. Patient Preference and Adherence 9, pages 281-287.
Read now
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Read now
Articles from other publishers (18)
Nawras Al-Taie, Delia Maftei, Alexandra Kautzky-Willer, Michael Krebs & Harald Stingl. (2019) Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents. Wiener klinische Wochenschrift 133:5-6, pages 167-172.
Crossref
Crossref
Silvio E. Inzucchi, Melanie J. Davies, Kamlesh Khunti, Prabhav Trivedi, Jyothis T. George, Isabella Zwiener, Odd Erik Johansen & Naveed Sattar. (2020)
Empagliflozin treatment effects across categories of baseline
HbA1c
, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
. Diabetes, Obesity and Metabolism 23:2, pages 425-433.
Crossref
Crossref
Jennifer Huynh, Holly Tschirhart Menezes, Hertzel Gerstein & Diana Sherifali. (2020) Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors. Canadian Journal of Diabetes 44:2, pages 184-191.
Crossref
Crossref
Craig I Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham & Brahim Bookhart. (2019) Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients. Journal of Comparative Effectiveness Research 8:11, pages 889-905.
Crossref
Crossref
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A. Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Matthew D. Culham, Jennifer B. Rose, Wally Rapattoni & Harpreet S. Bajaj. (2018) CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes, Obesity and Metabolism 21:3, pages 691-699.
Crossref
Crossref
Fukumi Yoshikawa, Naoki Kumashiro, Fumika Shigiyama, Hiroshi Uchino, Yasuyo Ando, Hiroshi Yoshino, Masahiko Miyagi, Kayoko Ikehara & Takahisa Hirose. (2019) Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial. Diabetes, Obesity and Metabolism 21:2, pages 303-311.
Crossref
Crossref
Hiroki Nakajima, Sadanori Okada, Takako Mohri, Eiichiro Kanda, Naoyuki Inaba, Yoko Hirasawa, Hiroaki Seino, Hisamoto Kuroda, Toru Hiyoshi, Tetsuji Niiya & Hitoshi Ishii. (2018) Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study). Diabetology & Metabolic Syndrome 10:1.
Crossref
Crossref
Liana K. BillingsYehuda HandelsmanMichael HeileDoron SchneiderKathleen Wyne. (2018) Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy 24:9-a Suppl, pages S30-S41.
Crossref
Crossref
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Simin Zhang, Lingli Zhou, Xueyao Han & Linong Ji. (2018) No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. Journal of Diabetes Investigation 9:4, pages 850-861.
Crossref
Crossref
Jennifer Cai, Linda M. Delahanty, Sydney Akapame, April Slee & Shana Traina. (2018) Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials. The Patient - Patient-Centered Outcomes Research 11:3, pages 341-352.
Crossref
Crossref
Shana B. Traina, April Slee, Suzy Van Sanden & Joris Diels. (2017) An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin. Diabetes Therapy 9:1, pages 125-140.
Crossref
Crossref
Nina A. Petunina, Anna L. Terekhova & Ekaterina V. Goncharova. (2016) Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor. Diabetes mellitus 19:6, pages 511-517.
Crossref
Crossref
Matthew Reaney, Celeste A. Elash & Leighann Litcher-Kelly. (2016) Patient Reported Outcomes (PROs) used in recent Phase 3 trials for Type 2 Diabetes: A review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials. Diabetes Research and Clinical Practice 116, pages 54-67.
Crossref
Crossref
Roberto Ravasio, Patrizia Pisarra, Roberto Porzio & Marco Comaschi. (2016) Economic Evaluation of Canagliflozin versus Glimepiride and Sitagliptin in Dual Therapy with Metformin for the Treatment of Type 2 Diabetes in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 3:2, pages GRHTA.5000229.
Crossref
Crossref
Erin K. Buysman, Wing Chow, Henry J. Henk & Marcia F. T. Rupnow. (2015) Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocrine Disorders 15:1.
Crossref
Crossref
Shana B. Traina, April Slee, Sangsoon Woo & William Canovatchel. (2015) The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes. Diabetes Therapy 6:4, pages 611-625.
Crossref
Crossref
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref